VLA 2001
Alternative Names: VLA-2001Latest Information Update: 23 Jan 2025
At a glance
- Originator Valneva
- Developer National Institute for Health Research; Valneva
- Class Adjuvants; Attenuated vaccines; COVID-19 vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered COVID 2019 infections
Most Recent Events
- 27 Apr 2024 Adverse events data from a phase II Cov-Boost trial in COVID-2019 infections presented at the 34th Congress of the European Society of Clinical Microbiology and Infectious (ESCMI-2024)
- 12 Oct 2023 Regulatory submission withdrawn for COVID-2019 infections (Prevention, In adults) in European Union (IM)
- 12 Oct 2023 Valneva withdraws the marketing authorization of VLA 2001 in COVID-19 in European Union